Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Sells $1,005,200.00 in Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Lantheus Price Performance

LNTH stock opened at $98.85 on Friday. The business has a fifty day moving average price of $92.64 and a 200 day moving average price of $96.70. Lantheus Holdings, Inc. has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 16.45 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of analyst reports. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Lantheus by 16.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,184 shares of the medical equipment provider’s stock valued at $374,000 after purchasing an additional 576 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Lantheus in the 4th quarter valued at $13,081,000. Mackenzie Financial Corp raised its position in shares of Lantheus by 4,907.1% during the fourth quarter. Mackenzie Financial Corp now owns 217,056 shares of the medical equipment provider’s stock worth $19,418,000 after acquiring an additional 212,721 shares during the last quarter. Peak Retirement Planning Inc. acquired a new position in shares of Lantheus during the fourth quarter valued at $917,000. Finally, Woodline Partners LP boosted its holdings in Lantheus by 2.7% in the fourth quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider’s stock valued at $7,874,000 after acquiring an additional 2,340 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.